{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:41:30Z","timestamp":1783564890547,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11-12","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.steroids.2006.07.003","type":"journal-article","created":{"date-parts":[[2006,8,29]],"date-time":"2006-08-29T12:21:22Z","timestamp":1156854082000},"page":"949-954","source":"Crossref","is-referenced-by-count":24,"title":["Novel phosphorus-containing 17\u03b2-side chain mifepristone analogues as progesterone receptor antagonists"],"prefix":"10.1016","volume":"71","author":[{"given":"Weiqin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Fiordeliso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gunnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lundeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2006.07.003_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0039-128X(00)00194-X","article-title":"Progesterone receptor modulators and progesterone antagonists in women's health","volume":"65","author":"Spitz","year":"2000","journal-title":"Steroids"},{"issue":"Suppl. 1","key":"10.1016\/j.steroids.2006.07.003_bib2_1","first-page":"11","article-title":"History and perspectives of antiprogestins from the chemist's point of view","volume":"9","author":"Teutsch","year":"1994","journal-title":"Human Repro"},{"key":"10.1016\/j.steroids.2006.07.003_bib2_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.steroids.2003.09.008","article-title":"Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy","volume":"68","author":"DaManno","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2006.07.003_bib2_3","doi-asserted-by":"crossref","first-page":"28468","DOI":"10.1074\/jbc.M504144200","article-title":"Molecular and pharmacological properties of a potent and selective novel non-steroidal progesterone receptor agonist Tanaproget","volume":"280","author":"Zhang","year":"2005","journal-title":"J Bio Chem"},{"key":"10.1016\/j.steroids.2006.07.003_bib3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1358\/dof.2002.027.11.857029","article-title":"Progesterone receptor antagonist (antiprogestins)","volume":"27","author":"Hess-Stumpp","year":"2002","journal-title":"Drugs Future"},{"key":"10.1016\/j.steroids.2006.07.003_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1749-6632.1995.tb31382.x","article-title":"Clinical uses of Mifepristone (MFP)","volume":"761","author":"Ulmann","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.steroids.2006.07.003_bib5_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/jc.76.2.513","article-title":"Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU-486","volume":"76","author":"Murphy","year":"1993","journal-title":"J Clin Endo Metab"},{"key":"10.1016\/j.steroids.2006.07.003_bib5_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0015-0282(16)54531-2","article-title":"Endocrine response to long-term administration of the antiprogesterone RU-486 in patients with pelvic endometriosis","volume":"56","author":"Kettel","year":"1991","journal-title":"Fertil Steril"},{"key":"10.1016\/j.steroids.2006.07.003_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0040-4020(98)01069-2","article-title":"Syntheses and GABA receptor binding properties of 4-amino-1-,2-, and 3-hydroxybutylphosphinic acids","volume":"55","author":"Kehler","year":"1999","journal-title":"Tetrahedron"},{"key":"10.1016\/j.steroids.2006.07.003_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/30775","article-title":"Atomic structure of progesterone complexed with its receptor","volume":"393","author":"Williams","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2006.07.003_bib8","doi-asserted-by":"crossref","first-page":"22748","DOI":"10.1074\/jbc.M212711200","article-title":"The three dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain","volume":"278","author":"Kauppi","year":"2003","journal-title":"J Bio Chem"},{"key":"10.1016\/j.steroids.2006.07.003_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0039-128X(98)00060-9","article-title":"New 11\u03b2-aryl-substituted steroids exhibit both progestational and antiprogestational activity","volume":"63","author":"Rao","year":"1998","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2006.07.003_bib10","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1016\/S0040-4039(97)10394-X","article-title":"Lithium Bis-(diisopropylamino)boracetylide [LiCC\u22efB(Ni\u22efPr2)2]. A New Reagent Preparation Term Alkynes","volume":"38","author":"Blanchard","year":"1997","journal-title":"Tet Lett"},{"key":"10.1016\/j.steroids.2006.07.003_bib11_1","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1016\/S0960-894X(02)00746-1","article-title":"New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles","volume":"12","author":"Fensome","year":"2002","journal-title":"Bio Med Chem Lett"},{"key":"10.1016\/j.steroids.2006.07.003_bib11_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0960-894X(03)00129-X","article-title":"Novel 5-aryl-1,3-dihydro-indole-2-thiones: potent, orally active progesterone receptor agonists","volume":"13","author":"Fensome","year":"2003","journal-title":"Bio Med Chem Lett"},{"key":"10.1016\/j.steroids.2006.07.003_bib11_3","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1021\/jm025555e","article-title":"6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists","volume":"45","author":"Zhang","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2006.07.003_bib11_4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0960-894X(03)00128-8","article-title":"Novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists","volume":"13","author":"Zhang","year":"2003","journal-title":"Bio Med Chem Lett"},{"key":"10.1016\/j.steroids.2006.07.003_bib12","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1021\/jm050358b","article-title":"Synthesis and SAR of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal PR agonist Tanaproget","volume":"48","author":"Fensome","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2006.07.003_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0960-0760(01)00091-7","article-title":"Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone","volume":"78","author":"Lundeen","year":"2001","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X06001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X06001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T20:50:15Z","timestamp":1547412615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X06001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":19,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0039128X06001590"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2006.07.003","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}